Last updated: September 21, 2026
Lonafarnib is marketed in the United States as Zokinvy, an orphan drug for Hutchinson-Gilford progeria syndrome and certain processing-deficient progeroid laminopathies. Its commercial profile is defined by a very small treated population, high per-patient revenue, orphan-drug exclusivity, specialized diagnosis and distribution requirements, and limited near-term generic pressure. Eiger BioPharmaceuticals commercialized Zokinvy through 2023 before financial distress and an asset transfer to Sentynl Therapeutics in 2024. The drug has not secured FDA approval for hepatitis delta virus, a larger potential indication that drove much of its development value.
What is lonafarnib approved to treat?
The FDA approved Zokinvy on November 20, 2020, for:
- Reducing the risk of mortality in patients aged 12 months and older with Hutchinson-Gilford progeria syndrome.
- Treating patients aged 12 months and older with certain processing-deficient progeroid laminopathies that cause significant mortality risk.
Zokinvy is an oral farnesyltransferase inhibitor. The product is supplied as 50 mg and 75 mg capsules and is administered with a fat-containing meal. The FDA approval was based on survival analyses and supportive clinical data in rare progeroid disorders rather than on a conventional large randomized registration program. The label includes gastrointestinal toxicity, vomiting, diarrhea, nausea, hepatic abnormalities, renal impairment, and drug-drug interaction risks.
The product’s approved indication is narrow. Zokinvy is not FDA-approved for oncology, hepatitis delta virus, or general anti-aging use. [1]
How large is the lonafarnib market?
The addressable market is small in patient count but large in revenue per patient.
| Market factor |
Assessment |
| Primary disease |
Hutchinson-Gilford progeria syndrome and selected progeroid laminopathies |
| Estimated global progeria population |
Approximately 400 to 500 identified patients, based on Progeria Research Foundation estimates |
| U.S. patient population |
Very small, generally estimated in the dozens rather than hundreds |
| Commercial model |
Orphan, specialist-driven, high-price therapy |
| Administration |
Chronic oral treatment |
| Main revenue driver |
Number of diagnosed and reimbursed patients, not broad prescription volume |
| Key commercial constraint |
Diagnosis, international access, reimbursement, and patient persistence |
| Main competitive threat |
Generic lonafarnib after relevant exclusivity and patent barriers expire |
| Biosimilar risk |
Not applicable because lonafarnib is a small-molecule drug |
The product’s revenue ceiling is constrained by disease prevalence. Price increases or expanded geographic coverage can materially affect sales, but the market cannot scale like a conventional specialty drug.
Eiger reported Zokinvy net sales of approximately $18 million in 2021, $28 million in 2022, and about $30 million in 2023. Reported sales reflected the product’s global launch progression, patient identification, reimbursement approvals, and treatment expansion rather than rapid volume growth. [2][3]
What is the financial trajectory for Zokinvy and lonafarnib?
Zokinvy became Eiger’s principal commercial asset, but its revenue base was not large enough to offset the company’s broader development and operating costs.
Eiger Zokinvy revenue trajectory
| Fiscal year |
Reported Zokinvy sales |
Commercial interpretation |
| 2020 |
Initial launch-period sales |
U.S. approval in November; limited partial-year contribution |
| 2021 |
Approximately $18 million |
Early patient identification and reimbursement buildout |
| 2022 |
Approximately $28 million |
Expanded international access and treated-patient growth |
| 2023 |
Approximately $30 million |
Continued orphan commercial growth, with a narrow patient pool |
| 2024 onward |
Not reported by Eiger as a continuing operating business |
Commercial rights transferred during restructuring |
Eiger entered Chapter 11 bankruptcy proceedings in April 2024. The restructuring impaired the value of a company built around several high-risk development programs, including lonafarnib for hepatitis delta virus. Sentynl Therapeutics acquired rights related to Zokinvy in 2024 and became the relevant commercial counterparty for the product in the United States. [4][5]
The transaction changed the ownership and commercialization structure, but it did not broaden the FDA-approved indication. The economic value of lonafarnib therefore remains tied primarily to progeria treatment and any future regulatory success in other diseases.
When does lonafarnib lose exclusivity?
Lonafarnib exclusivity has several separate components. The most important dates are the orphan-drug exclusivity period, regulatory exclusivity, and patent term.
Regulatory exclusivity
The FDA granted Zokinvy orphan-drug designation for its approved rare disease uses. Orphan-drug exclusivity generally lasts seven years from approval and prevents FDA approval of the same drug for the same disease or condition, subject to statutory exceptions.
For a November 20, 2020 approval, the seven-year orphan exclusivity period generally runs to November 20, 2027. Orphan exclusivity does not block every possible generic or competing product. It is indication-specific and does not eliminate patent rights or prevent all off-label use.
Zokinvy also received pediatric exclusivity, if applicable to the FDA’s final exclusivity record, which can add six months to certain listed exclusivity periods. The operative date must be confirmed through FDA’s current Orange Book and exclusivity listings. [6]
Patent expiration
The relevant patent expiration date cannot be reduced to the drug’s original composition-of-matter patent alone. Commercial protection can include:
- Lonafarnib composition patents.
- Salt, crystal, or solid-state patents.
- Capsule and oral formulation patents.
- Manufacturing and purification patents.
- Method-of-use patents covering progeroid syndromes.
- Patents covering specific dosing or treatment combinations.
FDA approval does not itself establish that every patent covering Zokinvy has been listed in the Orange Book. Patent expiration dates must be evaluated patent by patent, including patent-term adjustment, patent-term extension, terminal disclaimers, and any pediatric extension.
The practical loss-of-exclusivity risk is therefore likely to develop in stages. Orphan exclusivity may expire in late 2027, while patent-based generic entry could occur later if valid and enforceable patents remain. A generic applicant could still challenge listed patents through an abbreviated new drug application and a Paragraph IV certification.
What is the Orange Book status of Zokinvy?
Zokinvy’s Orange Book position should be assessed through three fields:
- Approved drug product and dosage forms.
- Listed patents and their use codes.
- FDA-recognized exclusivity periods.
For an oral small-molecule product, a prospective generic applicant would typically evaluate an ANDA pathway. The applicant could file:
- Paragraph I certification if no patent is listed.
- Paragraph II certification if a listed patent has expired.
- Paragraph III certification accepting delay until patent expiration.
- Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed.
A Paragraph IV notice to the NDA holder could trigger a 45-day period for patent litigation. A timely infringement action generally can create a 30-month stay of final FDA approval, subject to statutory exceptions and court developments. [7]
There is no biosimilar pathway for lonafarnib. The relevant challenge route is generic-drug litigation under the Hatch-Waxman framework.
What patents protect lonafarnib and Zokinvy?
The patent estate should be separated into core molecule protection and secondary protection.
Core molecule protection
Lonafarnib was discovered before Zokinvy’s approval and was investigated in oncology and infectious disease programs. Earlier compound patents may have expiration dates that are closer than later formulation or use patents. The commercial importance of those patents depends on whether they cover lonafarnib itself, a pharmaceutically acceptable form, or a specific use.
Formulation and dosage protection
Zokinvy is administered chronically and has clinically important food-effect and tolerability considerations. Patents directed to capsule composition, particle characteristics, dosing, or administration with food could delay or complicate a generic launch even after core compound protection ends.
Formulation patents are usually less powerful than a valid composition-of-matter patent because an ANDA applicant may attempt to design around them. Their practical strength depends on claim scope, FDA listing, infringement risk, and whether the generic product must use the same formulation to obtain approval.
Method-of-use protection
The approved use in progeroid laminopathies may support method-of-use patent claims. Use patents can have commercial value where the indication is rare and the product has no broad substitute. Their effect on generic entry depends on use-code accuracy and whether the generic applicant can carve out the patented indication from its labeling.
A skinny-label strategy may allow a generic applicant to market the drug for non-patented uses while excluding protected indications. For Zokinvy, the small size of the approved market reduces the commercial value of a carve-out unless the generic can legally and practically serve the same patient population without the protected use.
How strong is the lonafarnib patent estate?
The patent estate is commercially meaningful but structurally narrower than the estate of a high-volume specialty product.
| Strength factor |
Impact on Zokinvy |
| Orphan population |
Supports pricing and reduces the incentive for immediate generic entry |
| Chronic treatment |
Increases annual revenue per patient |
| Small patient base |
Limits generic market opportunity |
| Complex diagnosis |
Raises the operational cost of market entry |
| Oral capsule dosage form |
Easier to reproduce than an injectable biologic |
| Method-of-use claims |
Can delay direct substitution if properly listed and enforceable |
| Formulation claims |
May create design-around opportunities |
| No biosimilar pathway |
Eliminates biologic interchangeability risk |
| Patent litigation economics |
Potentially weaker because the total market is small |
The estate’s commercial strength is greater than its absolute market size. A generic company may face technical and legal barriers, but the expected sales opportunity may not justify lengthy Paragraph IV litigation unless the generic can obtain a large share of the global market or use lonafarnib for an additional approved indication.
Which companies are challenging lonafarnib?
No broadly reported commercial competitor has established an FDA-approved alternative to Zokinvy for progeria. The most relevant future challengers are likely to be:
- ANDA applicants seeking generic lonafarnib approval.
- Pharmaceutical companies developing alternative farnesyltransferase inhibitors.
- Developers pursuing gene therapy or other disease-modifying approaches for progeroid disorders.
- Companies developing treatments for hepatitis delta virus, where lonafarnib remains unapproved.
The competitive landscape is therefore more dependent on regulatory and scientific substitution than on direct branded competition.
What patent litigation affects Zokinvy?
Publicly visible litigation risk centers on possible future Paragraph IV activity and disputes over listed formulation or method-of-use patents. There has been no widely reported, market-defining Paragraph IV settlement involving Zokinvy comparable to litigation surrounding major mass-market drugs.
If a generic challenge emerges, the likely issues would include:
- Whether the asserted patent is listed for the approved product.
- Whether the generic label induces infringement.
- Whether the generic can carve out progeria-related uses.
- Whether formulation claims are technically infringed.
- Whether the patent is valid in view of earlier lonafarnib development.
- Whether the small market supports litigation through trial and appeal.
A settlement could establish a licensed entry date before the latest patent expiration. The economics would depend on the size of the generic applicant’s expected market and the patent holder’s willingness to preserve orphan pricing.
What is the regulatory status of lonafarnib for hepatitis delta virus?
Lonafarnib has been studied for chronic hepatitis delta virus infection, often in combination with ritonavir to increase lonafarnib exposure. The program was strategically important because hepatitis delta has a substantially larger potential population than progeria.
The D-LIVR Phase 3 study did not meet its primary efficacy endpoint in the relevant treatment comparison. Eiger subsequently discontinued further development of lonafarnib for hepatitis delta virus. Lonafarnib therefore does not have FDA approval for hepatitis delta virus, and no hepatitis delta revenue should be included in the base-case Zokinvy forecast. [8][9]
This failure materially reduced the drug’s growth option. A successful hepatitis delta approval could have converted lonafarnib from an ultra-orphan product into a broader specialty antiviral. That scenario is no longer the central commercial case.
What generic launch scenarios exist for lonafarnib?
Scenario 1: No generic before the late 2020s
This is the most commercially favorable scenario for the branded product. Orphan exclusivity, patents, limited patient numbers, and the absence of a large direct competitor preserve pricing and supply continuity.
Scenario 2: Paragraph IV challenge after orphan exclusivity
A generic applicant could target listed patents after the November 2027 orphan-exclusivity period. Litigation could produce a 30-month stay or an earlier settlement date.
Scenario 3: Authorized generic or licensed entry
The rights holder could license a generic manufacturer or introduce an authorized generic to retain supply-chain control and capture price-sensitive demand. This would likely reduce net price and could alter reimbursement terms.
Scenario 4: Delayed or limited generic launch
Even after FDA approval, a generic may launch cautiously because of low patient volume, specialized prescriber networks, reimbursement complexity, and manufacturing economics.
How does lonafarnib compare with other orphan drugs?
Lonafarnib has a stronger commercial position than its patient count suggests because it addresses a life-threatening disease with no broadly established substitute. Its weaknesses are the small population, the absence of a second approved indication, and the limited ability to generate scale.
Compared with biologic orphan drugs, lonafarnib has lower manufacturing complexity and no biosimilar barrier. Compared with conventional small-molecule specialty products, it has a more defensible commercial niche because diagnosis is highly specialized and treatment is concentrated among expert centers.
The key distinction is between pricing power and growth potential. Zokinvy can support high revenue per patient, but the total market remains capped unless the FDA approves another indication.
What is the outlook for lonafarnib revenue?
The base-case outlook is stable-to-modest growth rather than rapid expansion.
Revenue depends on:
- Newly diagnosed progeria patients.
- Treatment initiation and persistence.
- Reimbursement approval in the United States.
- Expansion into countries with recognized progeria centers.
- Price and contracting decisions by Sentynl.
- Generic entry timing.
- Any successful regulatory strategy for an additional indication.
The hepatitis delta failure removes the main path to a large revenue expansion. The product can remain commercially valuable as an ultra-orphan therapy, but it is unlikely to become a large pharmaceutical franchise without a new approved use.
Key Takeaways
- Lonafarnib is marketed as Zokinvy for Hutchinson-Gilford progeria syndrome and selected progeroid laminopathies.
- FDA approval occurred on November 20, 2020.
- Orphan-drug exclusivity generally reaches November 20, 2027, subject to the FDA’s final exclusivity record and any applicable pediatric extension.
- Eiger reported Zokinvy sales of approximately $18 million in 2021, $28 million in 2022, and about $30 million in 2023.
- Eiger entered Chapter 11 in 2024, and Sentynl Therapeutics acquired relevant Zokinvy commercial rights.
- Lonafarnib is not FDA-approved for hepatitis delta virus after failure of the D-LIVR development program.
- Generic risk is more relevant than biosimilar risk because lonafarnib is a small molecule.
- The commercial patent estate may include formulation and method-of-use protection, but exact entry timing depends on current Orange Book listings and enforceable patent claims.
- The product’s strongest assets are orphan pricing, specialist diagnosis, and limited direct competition.
- Its main weaknesses are the very small patient population and lack of a second approved indication.
FAQs about lonafarnib market and exclusivity
Is lonafarnib a biologic or a small-molecule drug?
Lonafarnib is an orally administered small-molecule farnesyltransferase inhibitor. Future competition would use the ANDA generic pathway rather than the biosimilar pathway.
What company owns Zokinvy?
Eiger BioPharmaceuticals originally commercialized Zokinvy. Sentynl Therapeutics acquired relevant Zokinvy rights during Eiger’s 2024 restructuring.
Can a generic launch before 2027?
A generic could theoretically be approved before the end of orphan exclusivity if it qualifies for a statutory exception, targets a different use, or obtains approval through a legally distinct route. Direct approval for the same protected orphan use is generally blocked during orphan exclusivity.
Why did lonafarnib fail to become a hepatitis delta drug?
The Phase 3 D-LIVR study did not meet its primary efficacy endpoint in the applicable treatment comparison. Eiger discontinued further development for hepatitis delta virus.
Is Zokinvy likely to face biosimilar competition?
No. Biosimilars apply to biological products. Zokinvy contains lonafarnib, a chemically synthesized small molecule, so any direct competitor would be a generic drug.
References
-
U.S. Food and Drug Administration. (2020). Zokinvy prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213969s000lbl.pdf
-
Eiger BioPharmaceuticals, Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2021. U.S. Securities and Exchange Commission.
-
Eiger BioPharmaceuticals, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
Eiger BioPharmaceuticals, Inc. (2024). Eiger BioPharmaceuticals files for Chapter 11 bankruptcy protection. Eiger BioPharmaceuticals.
-
Sentynl Therapeutics, Inc. (2024). Sentynl acquires commercial rights to Zokinvy. Sentynl Therapeutics.
-
U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA. https://www.fda.gov/industry/developing-products-rare-diseases-conditions/orphan-drug-designation-and-exclusivity
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
Eiger BioPharmaceuticals, Inc. (2023). Eiger discontinues development of lonafarnib for hepatitis delta virus. Eiger BioPharmaceuticals.
-
U.S. National Library of Medicine. (2023). D-LIVR: Lonafarnib with ritonavir for chronic hepatitis delta virus infection. ClinicalTrials.gov.
